ARS Pharmaceuticals : FDA has posted an Addendum to Briefing

FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom





... | May 9, 2023

Related Keywords

United States , Harlor Jr , Camargo Jr , Epipen , Adkinson Jr , Division Of Pulmonology , Office Of Immunology , Ars Pk Pd Program Development , R Joint Task Force On Practice Parameters , Advisory Committee , Pediatric Development , Office Of New Drugs , Kaleo Inc , Clinical Pharmacology Development Plan , While The Division , Emergency Department , Drug Administration , Adamis Pharms Corp , Impax Labs Inc , Intranasal Epinephrine Pk Pd Development Program , Community Settings , Data On Approved Epinephrine Injection Products , Pediatric Research Equity , Second National Institute Of Allergy , Development Of Other Emergency , Clinical Program , Division Or Office , Clinical Pharmacology Development Program , Key Aspects Of Development Program , Pertinent Drug Development , Anaphylaxis Network , Administration Issue , Briefing Document , Critical Care , New Drugs , Drug Evaluation , Preview Division , Draft Points , Brief Description , Key Aspects , Development Program , Key Results , Clinical Care , Epinephrine Injection Products , Regulatory History , Epinephrine Regulatory History , Efficacy Issues , Clinical Pharmacology Summary , Safety Issues , Benefit Risk Framework , Nonclinical Supportive Data , Nasal Mucosal Damage , Human Factors , Human Factors Overview , Human Factors Discussion , Pharmacology Development Plan , Epinephrine Products , Single Dose , Intramuscular Injection Using Adrenalin , Healthy Subjects , Subjects Who Failed , Following Two Doses , Same Naris , Opposite Naris , Intramuscular Injection Using Epipen , Two Doses , From Baseline , Following Repeat Doses , Subjects With Allergic Rhinitis , Adverse Events Occurring , Treatment Arm , Primary Safety Population , Safety Pooling , Geometric Mean , Standard Error , Concentration Time Profile Following , Plasma Concentration Time Profiles , Concentration Time Profile , Single Dose Epipen , Single Dose Adrenalin , Across Studies , Epinephrine Concentrations , Time Following , Concentration Time Profile Following Two Doses , Subjects With Epinephrine Concentrations , Greater Following Two Doses , Predose Nasal Congestion Score , Subgroup Analysis , Without Nasal Allergen Challenge , Nasal Congestion Score Subgroup Analysis , Plasma Concentration Time Profiles Following , Staff Administered From , Self Administered Single Dose , Pediatric Subjects , Adult Healthy Subjects From Study , Blister Pack With , Nasal Spray Device , Pharmacology Development Program , Pharmacology Development , Unlimited Data , Approved Epinephrine Injection , Federal Food , Cosmetic Act , Drug Efficacy Study Implementation , Healthy Volunteers , Clinical Pharmacology , Adrenalin Geometric Mean Concentration Time , Allergen Induced Nasal , Epinephrine Dosing , Subjects With Allergic , Allergen Induced Nasal Congestion , Pharmacology Review , Drug Development , Drugs Act , Mylan Specialty , Authorized Generic , Impax Labs , Epinephrine Injection , Pediatric Research Equity Act , Efficacy Trial , Cross Discipline Team Leader Review , Narcan Nasal Spray , Approved Epinephrine Injection Products , Bioequivalence Guidance , Following Repeat , Without Nasal Allergen , Time Profiles , Nasal Congestion Score Subgroup , After Dosing , Volunteer Studies , Risk Framework , Int Arch Allergy Immunol , Intensive Care , Arch Dis Child , Ann Allergy Asthma Immunol , Paediatric Exploitation , Document Step , Ann Emerg Med , Fed Proc , Curr Opin Allergy Clin Immunol , Biomed Res Int , Clin Exp Allergy , Second National Institute , Food Allergy , Practice Parameters , Fatal Anaphylaxis , Mortality Rate , Risk Factors , Adrenergic Agonists , Pharmacological Basis , Human Factors Studies , Related Clinical Study Considerations , Combination Product Design , Bioavailability Studies Submitted , Supportive Data , Mucosal Damage Changes , Factors Overview , Complete Submission , Threshold Analyses , Human Factors Submissions , Current Applicant , Human Factors Validation Study , Use Issues Uncovered , Mitigations Implemented , Address Use Issues Identified After , Use Error , Factors Discussion , Ars Pharmaceuticals , Nc Stock Exchange , News , Information , Press Release , Fda , Gas , Osted , N , Addendum , O , Briefing , Document , Its , Website , Hat , Recirculated , Members , F , He Spry Us82835w1080 ,